Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.95
INCY's Cash to Debt is ranked lower than
80% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. INCY: 0.95 )
Ranked among companies with meaningful Cash to Debt only.
INCY' s 10-Year Cash to Debt Range
Min: 0.35  Med: 1.26 Max: No Debt
Current: 0.95
Equity to Asset 0.06
INCY's Equity to Asset is ranked lower than
92% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. INCY: 0.06 )
Ranked among companies with meaningful Equity to Asset only.
INCY' s 10-Year Equity to Asset Range
Min: -1.83  Med: 0.07 Max: 0.82
Current: 0.06
-1.83
0.82
F-Score: 5
Z-Score: 13.75
M-Score: -1.91
WACC vs ROIC
1.89%
68.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 4.65
INCY's Operating margin (%) is ranked higher than
73% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. INCY: 4.65 )
Ranked among companies with meaningful Operating margin (%) only.
INCY' s 10-Year Operating margin (%) Range
Min: -4064.53  Med: -60.79 Max: 9.05
Current: 4.65
-4064.53
9.05
Net-margin (%) 2.06
INCY's Net-margin (%) is ranked higher than
69% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. INCY: 2.06 )
Ranked among companies with meaningful Net-margin (%) only.
INCY' s 10-Year Net-margin (%) Range
Min: -4565.45  Med: -82.36 Max: 7.67
Current: 2.06
-4565.45
7.67
ROA (%) 1.63
INCY's ROA (%) is ranked higher than
78% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. INCY: 1.63 )
Ranked among companies with meaningful ROA (%) only.
INCY' s 10-Year ROA (%) Range
Min: -70.43  Med: -20.38 Max: 5.19
Current: 1.63
-70.43
5.19
ROC (Joel Greenblatt) (%) 81.16
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. INCY: 81.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4727.38  Med: -137.90 Max: 38.66
Current: 81.16
-4727.38
38.66
Revenue Growth (3Y)(%) 59.60
INCY's Revenue Growth (3Y)(%) is ranked higher than
93% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. INCY: 59.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INCY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.4  Med: 19.50 Max: 194.1
Current: 59.6
-61.4
194.1
EPS Growth (3Y)(%) -42.00
INCY's EPS Growth (3Y)(%) is ranked lower than
88% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. INCY: -42.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
INCY' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.1  Med: -8.70 Max: 64.9
Current: -42
-45.1
64.9
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

INCY Guru Trades in Q3 2014

Jim Simons 97,916 sh (New)
Mariko Gordon 25,283 sh (+6.55%)
Vanguard Health Care Fund 10,174,343 sh (+6.08%)
Mariko Gordon 16,500 sh (unchged)
Louis Moore Bacon Sold Out
Ken Fisher 7,545 sh (-38.28%)
» More
Q4 2014

INCY Guru Trades in Q4 2014

Jim Simons 244,800 sh (+150.01%)
Ken Fisher 14,870 sh (+97.08%)
Vanguard Health Care Fund 10,174,343 sh (unchged)
Mariko Gordon Sold Out
» More
Q1 2015

INCY Guru Trades in Q1 2015

Vanguard Health Care Fund 10,174,343 sh (unchged)
Ken Fisher 14,870 sh (unchged)
Jim Simons Sold Out
» More
Q2 2015

INCY Guru Trades in Q2 2015

Jim Simons 275,000 sh (New)
Joel Greenblatt 10,363 sh (New)
Vanguard Health Care Fund 9,411,543 sh (-7.50%)
Ken Fisher 13,695 sh (-7.90%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 2172.03
INCY's P/E(ttm) is ranked lower than
99% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. INCY: 2172.03 )
Ranked among companies with meaningful P/E(ttm) only.
INCY' s 10-Year P/E(ttm) Range
Min: 1924.53  Med: 1996.23 Max: 2262.83
Current: 2172.03
1924.53
2262.83
Forward P/E 136.99
INCY's Forward P/E is ranked lower than
89% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. INCY: 136.99 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 3997.70
INCY's PE(NRI) is ranked lower than
100% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. INCY: 3997.70 )
Ranked among companies with meaningful PE(NRI) only.
INCY' s 10-Year PE(NRI) Range
Min: 3400  Med: 3526.67 Max: 3997.67
Current: 3997.7
3400
3997.67
P/B 371.35
INCY's P/B is ranked lower than
100% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. INCY: 371.35 )
Ranked among companies with meaningful P/B only.
INCY' s 10-Year P/B Range
Min: 8.66  Med: 23.62 Max: 386.87
Current: 371.35
8.66
386.87
P/S 30.78
INCY's P/S is ranked lower than
74% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. INCY: 30.78 )
Ranked among companies with meaningful P/S only.
INCY' s 10-Year P/S Range
Min: 7.19  Med: 24.01 Max: 209.75
Current: 30.78
7.19
209.75
PFCF 348.82
INCY's PFCF is ranked lower than
94% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. INCY: 348.82 )
Ranked among companies with meaningful PFCF only.
INCY' s 10-Year PFCF Range
Min: 7.24  Med: 19.26 Max: 941.29
Current: 348.82
7.24
941.29
POCF 255.82
INCY's POCF is ranked lower than
94% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. INCY: 255.82 )
Ranked among companies with meaningful POCF only.
INCY' s 10-Year POCF Range
Min: 7.19  Med: 123.71 Max: 732.11
Current: 255.82
7.19
732.11
EV-to-EBIT 336.93
INCY's EV-to-EBIT is ranked lower than
95% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. INCY: 336.93 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s 10-Year EV-to-EBIT Range
Min: -3055.7  Med: -5.95 Max: 3083.6
Current: 336.93
-3055.7
3083.6
Current Ratio 3.81
INCY's Current Ratio is ranked lower than
53% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. INCY: 3.81 )
Ranked among companies with meaningful Current Ratio only.
INCY' s 10-Year Current Ratio Range
Min: 1.51  Med: 4.08 Max: 21.14
Current: 3.81
1.51
21.14
Quick Ratio 3.80
INCY's Quick Ratio is ranked lower than
51% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. INCY: 3.80 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s 10-Year Quick Ratio Range
Min: 1.51  Med: 4.08 Max: 21.14
Current: 3.8
1.51
21.14
Days Inventory 32.82
INCY's Days Inventory is ranked higher than
84% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. INCY: 32.82 )
Ranked among companies with meaningful Days Inventory only.
INCY' s 10-Year Days Inventory Range
Min: 46.41  Med: 198.14 Max: 323.15
Current: 32.82
46.41
323.15
Days Sales Outstanding 42.55
INCY's Days Sales Outstanding is ranked higher than
68% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. INCY: 42.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s 10-Year Days Sales Outstanding Range
Min: 12.25  Med: 50.81 Max: 6447.52
Current: 42.55
12.25
6447.52

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 371.35
INCY's Price/Tangible Book is ranked lower than
100% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. INCY: 371.35 )
Ranked among companies with meaningful Price/Tangible Book only.
INCY' s 10-Year Price/Tangible Book Range
Min: 0.9  Med: 5.51 Max: 336.16
Current: 371.35
0.9
336.16
Price/Median PS Value 1.34
INCY's Price/Median PS Value is ranked lower than
65% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. INCY: 1.34 )
Ranked among companies with meaningful Price/Median PS Value only.
INCY' s 10-Year Price/Median PS Value Range
Min: 0.1  Med: 0.68 Max: 7.03
Current: 1.34
0.1
7.03
Price/Graham Number 162.14
INCY's Price/Graham Number is ranked lower than
99% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. INCY: 162.14 )
Ranked among companies with meaningful Price/Graham Number only.
INCY' s 10-Year Price/Graham Number Range
Min: 4.08  Med: 6.90 Max: 146.77
Current: 162.14
4.08
146.77
Earnings Yield (Greenblatt) (%) 0.30
INCY's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. INCY: 0.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INCY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 0.80 Max: 1.3
Current: 0.3
0.1
1.3

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 708 980 1,454
EPS($) -0.17 0.84 2.40 4.21
EPS without NRI($) -0.17 0.84 2.40 4.21

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ICY.Germany,
Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 

More From Other Websites
Analyzing Incyte: What Kind of Company Is It? Sep 02 2015
INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Sep 02 2015
5:35 am Incyte signs GLA with Jiangsu Hengrui Medicine for SHR-1210; Incyte to pay Hengrui $25... Sep 02 2015
Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an... Sep 02 2015
Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an... Sep 02 2015
Incyte Was a Star Performer from August 10–17, 2015 Sep 01 2015
Incyte to Present at Upcoming Investor Conferences Sep 01 2015
Incyte to Present at Upcoming Investor Conferences Sep 01 2015
Incyte, Signet, Sportsman's Flirt With Breakouts Aug 31 2015
3 Under-The-Radar Biotech Stocks With Bullish Charts Aug 31 2015
XBI Remains Flat as of August 17, 2015 Aug 31 2015
INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Aug 25 2015
Top 10 Funds & Stocks at Risk of Being Squeezed in Market Turmoil Aug 25 2015
Incyte Named 7th Most Innovative Company in the World by Forbes Magazine Aug 21 2015
Incyte Named 7th Most Innovative Company in the World by Forbes Magazine Aug 21 2015
Coverage initiated on Incyte by Barclays Aug 13 2015
INCYTE CORP Financials Aug 11 2015
Why Incyte Corporation (INCY) Might Be a Diamond in the Rough - Tale of the Tape Aug 11 2015
10-Q for Incyte Corp. Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK